Famciclovir for the Management of Genital Herpes Simplex in Patients with Inadequate Response to Aciclovir or Valaciclovir
- 14 Downloads
KeywordsHerpes Simplex Virus Immunocompromised Patient Genital Herpes Immunocompetent Patient Herpes Simplex Virus Infection
This study was supported by a research grant provided by Novartis. Dr Sacks had no potential conflicts of interest that are directly relevant to the contents of this article. Dr Aoki has received payments from Novartis for participation in their clinical trials and for speaking at symposia sponsored by Novartis.
We thank all the physicians who were involved with the study, particularly the principal investigators: Mark O’Loveless (Portland, OR); Stephen Sacks (Vancouver, BC); Javier Morales-Ramirez (San Juan, Puerto Rico); Adelaide A. Herbert (Houston, TX); George Harb (Ft Lauderdale, FL); Jerry C. Stern (New York); Terri Warren (Portland, OR).
- 2.de Miranda P, Blum MR. Pharmacokinetics of aciclovir after intravenous and oral administration. J Antimicrob Chemother 1983; 12Suppl. B: 29–37Google Scholar
- 5.Boyd MR, Safrin S, Kern ER. Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antivir Chem Chemother 1993; 4Suppl. 1: 3–11Google Scholar
- 8.Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antivir Chem Chemother 1993; 4Suppl. 1: 47–55Google Scholar
- 10.Vere Hodge RA, Darlison SJ, Earnshaw DL, et al. Use of isotopically chiral [4′-13C]penciclovir and 13C NMR to determine the specificity and absolute configuration of penciclovir phosphate esters formed in HSV-1 and HSV-2 infected cells and by HSV-1-encoded thymidine kinase. Chirality 1993; 5: 583–8CrossRefGoogle Scholar